Fractionated Radiotherapy Improves Cancer Surgery Results
By MedImaging International staff writers Posted on 23 Feb 2017 |
Short-course preoperative radiotherapy (RT) combined with delayed surgery reduces the adverse side effects of rectal cancer surgery, according to a new study.
Researchers at Karolinska Institutet, Uppsala University, and other institutions conducted a phase 3 non-inferiority trial involving 840 patients from 18 Swedish hospitals who were randomized to three different RT regimens, with respect to fractionation and time to surgery. All patients suffered from biopsy-proven adenocarcinoma of the rectum, without signs of non-resectability or distant metastases, without severe cardiovascular comorbidity, and with planned abdominal resection.
The participants were randomly assigned with permuted blocks, stratified by participating center, to receive either 5 × 5 Gy radiation dose with surgery within one week (short-course radiotherapy), or after 4–8 weeks (short-course radiotherapy with delay), or 25 × 2 Gy radiation dose with surgery after 4–8 weeks (long-course radiotherapy with delay). The primary endpoint was time to local recurrence, as calculated from the date of randomization to the date of local recurrence.
The results showed that in patients with any local recurrence, median time from date of randomization to local recurrence in the short-course RT comparison was 33.4 months; in the short-course RT group, it was 19.3 months; and in the long-course RT with delay group it was 33.3 months. Postoperative complications were similar between all three arms; however, the risk of postoperative complications was significantly lower after short-course RT with delay. The study was published on February 9, 2017, in The Lancet Oncology.
“The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,” said senior author Professor Anna Martling, PhD, of the KI department of molecular medicine and surgery. “It also showed that there is no difference between long-course and short-course radiotherapy, other than that the former considerably lengthens the time for treatment.”
When the total dose of radiation is fractionated into several, smaller doses over a period of several days, there are fewer toxic effects on healthy cells. Typical fractionation schemes divide the radiation dose into units delivered every weekday over about six weeks. The logic behind the treatment is that applying greater amounts of radiation works to lower the effects of accelerated tumor growth that typically occurs during the later stages of RT.
Researchers at Karolinska Institutet, Uppsala University, and other institutions conducted a phase 3 non-inferiority trial involving 840 patients from 18 Swedish hospitals who were randomized to three different RT regimens, with respect to fractionation and time to surgery. All patients suffered from biopsy-proven adenocarcinoma of the rectum, without signs of non-resectability or distant metastases, without severe cardiovascular comorbidity, and with planned abdominal resection.
The participants were randomly assigned with permuted blocks, stratified by participating center, to receive either 5 × 5 Gy radiation dose with surgery within one week (short-course radiotherapy), or after 4–8 weeks (short-course radiotherapy with delay), or 25 × 2 Gy radiation dose with surgery after 4–8 weeks (long-course radiotherapy with delay). The primary endpoint was time to local recurrence, as calculated from the date of randomization to the date of local recurrence.
The results showed that in patients with any local recurrence, median time from date of randomization to local recurrence in the short-course RT comparison was 33.4 months; in the short-course RT group, it was 19.3 months; and in the long-course RT with delay group it was 33.3 months. Postoperative complications were similar between all three arms; however, the risk of postoperative complications was significantly lower after short-course RT with delay. The study was published on February 9, 2017, in The Lancet Oncology.
“The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,” said senior author Professor Anna Martling, PhD, of the KI department of molecular medicine and surgery. “It also showed that there is no difference between long-course and short-course radiotherapy, other than that the former considerably lengthens the time for treatment.”
When the total dose of radiation is fractionated into several, smaller doses over a period of several days, there are fewer toxic effects on healthy cells. Typical fractionation schemes divide the radiation dose into units delivered every weekday over about six weeks. The logic behind the treatment is that applying greater amounts of radiation works to lower the effects of accelerated tumor growth that typically occurs during the later stages of RT.
Latest Nuclear Medicine News
- New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment